Monitoring Antimalarial Safety and Tolerability in Clinical Trials in Uganda
Author Information
Author(s): Sarah G Staedke, Prasanna Jagannathan, Adoke Yeka, Hasifa Bukirwa, Kristin Banek, Catherine Maiteki-Sebuguzi, Tamara D Clark, Bridget Nzarubara, Denise Njama-Meya, Arthur Mpimbaza, Philip J Rosenthal, Moses R Kamya, Fred Wabwire-Mangen, Grant Dorsey, Ambrose O Talisuna
Primary Institution: London School of Hygiene & Tropical Medicine
Hypothesis
How can we effectively monitor the safety and tolerability of antimalarial treatments in clinical trials?
Conclusion
New guidelines for monitoring safety and tolerability in antimalarial trials are needed to improve the assessment of adverse events.
Supporting Evidence
- 5,614 treatments were evaluated in 4,876 patients across eleven trials.
- Serious adverse events were uncommon, with convulsions being the most reported.
- Clinical treatment failure confounded associations between treatment and adverse events.
- Standardized guidelines for monitoring adverse events are lacking.
Takeaway
This study looked at how to keep track of side effects from malaria treatments in Uganda, and found that better rules are needed to do this well.
Methodology
The study involved eleven randomized, controlled clinical trials comparing different antimalarial regimens, with a focus on monitoring adverse events.
Potential Biases
Differences in treatment practices and reporting standards may introduce bias in adverse event classification.
Limitations
Variability in baseline characteristics and adverse event reporting across study sites limited data pooling and analysis.
Participant Demographics
Participants included children aged 0.5 to 10 years, with varying malaria transmission intensity across different sites.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website